Study of levosimendan in adults with severe heart failure
Part of Heart & circulation clinical trials.
This study looks at how a heart medication called levosimendan works in the body of adults with severe cardiogenic shock. It aims to improve dosing for better outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old and currently in an intensive care unit.
- You weigh at least 50 kg (about 110 lbs).
- You have a specific type of severe heart failure called cardiogenic shock (stage C, D, or E).
- Your doctors plan to give you a drug called levosimendan to help your heart pump.
- Your expected survival is more than 48 hours.
- You are not pregnant, breastfeeding, or under legal guardianship.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether giving levosimendan early (a heart-strengthening medicine) improves outcomes compared with placebo, on top of standard inotropic support, in people with cardiogenic shock. It mainly looks at whether patients have fewer serious complications or deaths.
This study tests a device that helps the heart pump blood when it is too weak to do so, even with medicine, after surgery, or while waiting for a transplant. It aims to see if it's safe and works well.
This trial tests if unloading the heart during ECMO support helps patients recover better from cardiogenic shock. It compares different ways to reduce the heart's workload.
This trial is testing a temporary heart pump device that helps your heart pump blood when it's too weak to do its job. It's for people who have severe heart failure (cardiogenic shock) despite getting powerful medications to keep their heart working.
This early study looks at how well the heart is pumping in people with cardiogenic shock, using measurements taken during a right-heart catheter (a small pressure-monitoring test). It may help doctors better assess heart function and guide next-step treatments like LVAD, heart transplant, or valve surgery.
This study tracks how well people with cardiogenic shock (a life-threatening drop in blood flow after a heart attack or heart failure worsening) do when treated with modern support devices and medicines.
Hear when a new Cardiogenic Shock trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.